# Real World Evidence of Benralizumab in Eosinophilic Severe AsThma in Russia (BEST)

> **NCT05271526** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 3 (actual)

## Conditions studied

- Severe Eosinophilic Asthma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05271526
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-16
- **Primary completion:** 2023-11-13
- **Final completion:** 2023-11-13
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2024-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05271526

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05271526, "Real World Evidence of Benralizumab in Eosinophilic Severe AsThma in Russia (BEST)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05271526. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*